Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. FDX
4. META
5. ABBV
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL

Teva Pharma (TEVA) PT Lowered to $15 at Morgan Stanley

October 5, 2017 8:58 AM EDT

Morgan Stanley lowered its price target on Teva Pharma (NYSE: TEVA) to $15.00 (from $16.00) while maintaining a Underweight rating.

... More